Meda acquires exclusive rights to new treatment for actinic keratosis from Graceway
Sweden-based Meda has acquired exclusive European rights to a new formulation of imiquimod from US drugmaker Graceway Pharmaceuticals. The new formulation is 3.75% imiquimod topical cream indicated for the treatment of actinic keratosis (AK). This product approved in the USA, under the trade name Zyclara, in March this year, and it has also been cleared in Canada.
At present, Meda markets a higher strength (5%) of imiquimod in Europe as Aldara, which generated 2009 sales of around 500 million Swedish kronor ($64.6 million). 3,75% imiquimod can be used on a significantly larger treatment area, it is once-daily and more tolerable due to the decreased concentration. The patent for this novel imiquimod formulation is pending.
'We have very good experience with Aldara in Europe and we look forward to provide AK patients with a new product with improved tolerability that builds on the efficacy of imiquimod,' says Anders Lonner, chief executive at Meda.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze